Para-[123I]iodo-L-phenylalanine in patients with pancreatic adenocarcinoma Tumour uptake, whole-body kinetics, dosimetry;Para-[123I]lod-L-phenylalanin bei Patienten mit Adenokarzinom des Pankreas Tumorale Aufnahme, Ganzkörperkinetik und Dosimetrie

NuklearMedizin

Volumn 47, Issue 5, 2008, Pages 220-224

  Hellwig, D ^a   Gouverneur, E ^a   Schaefer, A ^a   Raedle, J ^a   Menges, M ^a   Kirsch, C M ^a   Samnick, S ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Amino acids; Pancreatic adenocarcinoma; Radiation dosimetry; Radiopharmaceuticals

Indexed keywords

4 IODOPHENYLALANINE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 4 IODOPHENYLALANINE; 4-IODOPHENYLALANINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PHENYLALANINE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DOSIMETRY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG TUMOR LEVEL; FEMALE; HUMAN; MALE; PANCREAS ADENOCARCINOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; HALF LIFE TIME; KINETICS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PANCREAS TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; WHOLE BODY RADIATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; KINETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHENYLALANINE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY IRRADIATION;

EID: 58149347650     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0152     Document Type: Article

References (23)

1. 123I]iodo-L-phenylalanine can be used in diagnostic nuclear medicine with acceptable radiation doses. Besides its proven validity for brain tumour imaging, IPA does not appear to be suitable as tracer for pancreatic cancer. Radiopharmaceuticals, amino acids, pancreatic adenocarcinoma, radiation dosimetry
2. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol 2007; 34: 284-294.
3. Cloutier RJ, Smith SA, Watson EE et al. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25:147-161.
4. Dey HM, Seibyl JP, Stubbs JB et al. Human biodistribution and dosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-iomazenil. J Nucl Med 1994; 35: 399-404.
5. 18F-fluorodeoxyglucose-positronemission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000;20:109-116.
6. 123I]iodoL-phenylalanine and SPECT Eur J Nucl Med Mol Imaging 2005; 32: 1041-1049.
7. Hellwig D, Menges M, Schneider G et al. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-d-glucose in human pancreatic carcinoma xenografts and in inflammation models. Nucl Med Biol 2005; 32:137-145.
8. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13: 601-609.
9. International Commission on Radiological Protection. 1990 Recommendations. ICRP Publication 60 ed. New York: Pergamon Press 1991.
10. Linder S, Bostrom L, Nilsson B. Pancreatic carcinoma incidence and survival in Sweden in 1980-2000: A population-based study of 16758 hospitalized patients with special reference to different therapies. Eur J Surg Oncol 2007; 33: 616-622.
11. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations Revised. New York: Society of Nuclear Medicine; 1991.
12. Macfarlane D, Gonin J, Wieland D et al. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabeled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue. Eur JNuclMed 1996; 23: 131-140.
13. rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-1723.
14. 131I]iodo-L-phenylalanine on primary human glioma cell cultures and rats with C6-gliomas. Anticancer Res 2004; 24: 3971-3976.
15. 123I]iodo-L- phenylalanine for routine brain tumour imaging. Nucl Med Comm 2002; 23: 121-130.
16. 123I]iodo-L- phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 532-541.
17. Samnick S, Schaefer A, Siebert S et al. Preparation and investigation of tumor affinity, uptake kinetic and transport mechanism of iodine123-labelled amino acid derivatives in human pancreatic carcinoma and glioblastoma cells. Nucl Med Biol 2001; 28: 13-23.
18. Snyder WS, Ford MR, Warner GG et al. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. New York: The Society of Nuclear Medicine 1975.
19. Sorensen JA. Quantitative measurement of radioactivity in vivo by whole-body counting. In: Hine GJ et al. (eds). Instrumentation in nuclear medicine. New York: Academic Press 1974:311-347.
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-1027.
21. Thomas SR, Stabin MG, Chen CT et al. MIRD Pamphlet No. 14 revised: A dynamic urinary bladder model for radiation dose calculations. Task Group of the MIRD Committee, Society of Nuclear Medicine. J Nucl Med 1999; 40: 102S-123S.
22. Tisljar U, Kloster G, Ritzl F et al. Accumulation of radioiodinated L-alpha-methyltyrosine in pancreas of mice: concise communication. J Nucl Med 1979; 20: 973-976.
23. Vander Borght T, Asenbaum S, Bartenstein P et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006; 33:1374-1380.